The P-II trial assesses the safety, efficacy, tolerability & PK profile of frexalimab (high dose: 1200mg, IV, Q4W with 1800mg loading dose & low dose: 300mg, SC, Q2W with 600mg loading dose) vs PBO to treat relapsing MS for 12wks. after which PBO patients will switch to frexalimab arms
The results showed, 96% (high dose) & 87% (low dose) of patients were Gd+ T1 lesion-free at wk.48 while those who switched had declines at wk.24 with 90% (high dose) & 92% (low dose) lesion-free at wk.48
At wk.48, new/growing Gd+ T2 lesions remained low with stable lymphocyte counts. ARR of 0.04 was seen at high dose with 96% free of relapses & 0.22 was seen at an initial low dose with 0.09 (high dose) & 0.40 (low dose) in those who switched
Ref: Globenewswire | Image: Sanofi
Related News:- Sanofi Reports Results for Frexalimab in P-II Trial for the Treatment of Relapsing Multiple Sclerosis (MS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
